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Practical aspects of the application 
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Joongyo Lee1,5, Euidam Kim2,5, Nalee Kim3, Hwa Kyung Byun1, Chang‑Ok Suh1,4, 
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We investigated the practical aspects of the application of craniospinal irradiation using helical 
tomotherapy (HT‑CSI) by evaluating interfractional setup errors and intrafractional movement 
during each treatment in 83 patients undergoing HT‑CSI between January 2014 and December 2018. 
Interfractional setup errors in each axis (mediolateral; ML, craniocaudal; CC, and anteroposterior; AP) 
were assessed as differences between pre‑treatment megavoltage computed tomography (MVCT) 
images scanned (zygomatic arch to the C4 spine) and planning CT images. Intrafractional movements 
were evaluated as the difference between pre‑treatment and post‑treatment MVCT (T12–L4 spine) 
images at each fraction. Median interfractional setup error was acceptable in every axis (ML: 1.6 mm, 
CC: 1.9 mm, AP: 3.1 mm). Seven patients (8.4%) experienced significant intrafractional displacement 
from 1 to 10 fractions (0.34% for ML, 0.74% for CC, 1.21% for AP). Weight loss grade 1+ during 
treatment (p = 0.016) was an independent risk factor for significant intrafractional displacement. 
The risk factor for significant intrafractional movement in pediatric patients was weight loss grade 
1+ (p = 0.020), while there was no factor in adults. HT‑CSI could be a feasible treatment modality with 
acceptable setup verification. Inter‑ and intrafractional errors were acceptable; paying attention to 
weight loss during treatment is necessary, especially in pediatric patients.
Craniospinal irradiation (CSI) is often needed in patients with brain tumors who are at risk of dispersion through 
the cerebrospinal  fluid1–4. CSI is a complex radiotherapy (RT) technique used for the cranium and spinal cord, 
with the movement of junctions along the lateral brain and spinal field of the patient.
Although three-dimensional conformal RT (3D-CRT) has been the most common and useful technique for 
CSI, CSI using 3D-CRT still has many limitations such as problems related to multiple isocenters, need for junc-
tion movement during treatment, and dose inhomogeneity at the beam  junctions5–7. Additionally, large areas 
of the organs at risk (OARs) near the target can be irradiated due to the low conformity of 3D-CRT compared 
to those of the latest RT  techniques6,8–10. These drawbacks of the 3D-CRT technique are highlighted by the fact 
that CSI is generally used for pediatric patients because they are known to have more severe side effects such as 
endocrine and fertility dysfunction, growth and musculoskeletal abnormalities, neurobehavioral deficits, and 
secondary malignancies due to unnecessary irradiation to  OARs4,11–14.
After 3D-CRT, many RT technologies have been developed, such as intensity-modulated RT including helical 
tomotherapy (HT), volumetric modulated arc therapy, and particle beam therapy, to overcome the limitations of 
3D-CRT and to make RT technique more accurate and  precise15–23. By using HT for CSI, treatment of extended 
volume along the craniocaudal direction and more homogeneous dose distribution is possible without any 
junction-related problems during treatment, owing to continuous helical delivery of the intensity-modulated 
fan beam in  HT24. In addition, treatment in a more comfortable position to the patient (both prone or supine) is 
possible, and daily patient position can be verified using megavoltage computed tomography (MVCT) at every 
treatment  fraction4,22,24–26. However, there are also some potential drawbacks of HT: poor image quality and 
setup uncertainty owing to the use of MVCT. In HT, problem of poor image quality has been raised as a one of 
the major limitations of MVCT imaging. Moreover, HT also involves setup uncertainty due to the relatively short 
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range of MVCT compared to the long range of the treatment field in the craniocaudal direction required for 
CSI using HT (HT-CSI)16,27,28. Among these drawbacks, in terms of the image quality, Forrest et al. and Meeks 
et al. reported that MVCT can provide sufficient image quality for tumor identification and setup verification, 
despite its low-contrast resolution for soft  tissues29,30. However, questions remain about setup uncertainty before 
or during treatment.
In this study, the clinical feasibility of HT-CSI was demonstrated by investigating the accuracy of setup 
in interfractional and intrafractional aspects, focusing on the median setup error and existence of significant 
movement during treatment in both groups, and identifying clinically significant risk factors for intrafractional 
movement.
Results
Patient characteristics. Median patient age at HT-CSI was 20.9 years (range, 12.1–31.2 years); 48.2% of 
patients were pediatric patients (patients under the age of 20 years). The most common pathology was germ cell 
tumor for pediatric patients (15 patients, 37.5%) and glioblastoma for adult patients (10 patients, 23.3%). The 
baseline characteristics of patients are summarized in Table 1.
With a median body mass index (BMI) of 20.4  kg/m2, 26 patients were categorized as underweight 
(BMI < 18.5 kg/m2), 50 were categorized to have normal weight (BMI 18.5–25 kg/m2), and 7 were categorized 
to have overweight (BMI 25–30 kg/m2) according to the World Health Organization  criteria31. Weight loss and 
nausea were evaluated according to Criteria for Adverse Events (CTCAE), version 5.0. There were 13 patients 
(15.7%) who experienced weight loss grade 1+ (≥ 5% from baseline) and 20 patients (24.1%) with nausea grade 
2+ (outpatient intravenous hydration; medical intervention indicated) during HT-CSI.
Table 1.  Patient and treatment characteristics. CSI craniospinal irradiation; Gy gray. *Based on common 
terminology criteria for adverse events version 5.0.
Characteristic N %
Age (years, median [range]) 21 (2–74)
< 20 years (pediatric) 40 48.2
≥ 20 years (adult) 43 51.8
Histology–Pediatric





Leptomeningeal carcinomatosis 7 16.3





Height (cm, median [range]) 165 (88–192)
Body-mass index (kg/m2, median [range]) 20.4 (10.9–28.4)
Weight loss grade ≥ 1* 13 15.7
Nausea grade ≥ 2* 20 24.1
Total CSI dose (Gy, median [range]) 36.0 (12.0–45.0)
Total CSI fraction number (fractions, median [range]) 20 (8–30)
Fractional CSI dose (Gy, median [range]) 1.5 (1.2–3.0)
CSI field
Brain-Sacrum 76 91.6
Posterior fossa-Sacrum 2 2.4
C1 spine-Sacrum 5 6.0
Beam on time (seconds, median [range]) 538.1 (310.6–964.8)
Sedation during treatment 7 8.4
Concurrent chemotherapy 29 34.9
Overall CSI treatment time (days, median [range]) 32 (11–108)
Medically-indicated treatment interruptions 28 33.7
Days (median [range]) 5 (1–58)
Adaptive during CSI 3 3.6
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Treatment characteristics. Treatment characteristics are listed in Table 1. The median total HT-CSI dose 
for all patients was 36.0 Gy (range, 12.0–45.0 Gy), with a median fractional dose of 1.5 Gy (range, 1.2–3.0 Gy). 
Most patients (76 patients, 91.6%) received HT-CSI from the whole brain to the sacral level, 5 (6.0%) received 
irradiation from the C1 spine level to the sacral level, and 2 (2.4%) received irradiation from the posterior fossa 
to the sacral level. The median beam on time was 538.1 s (range, 310.6–964.8 s). Concurrent chemotherapy was 
administered to 29 patients (34.9%).
The median overall treatment time for HT-CSI was 32 days (range, 11–108 days), and in 28 patients (33.7%), 
treatment was interrupted mainly due to thrombocytopenia. Of the 28 patients, adaptive treatment planning 
was performed on newly taken simulation computed tomography (CT) images in 3 patients due to long-term 
treatment interruption.
Interfractional setup errors. The interfractional setup errors obtained from each axis are summarized 
in Fig.  1. Median values of median shifts in the mediolateral (ML), craniocaudal (CC), and anteroposterior 
(AP) axes were 1.6 mm (inter-quartile range [IQR] 1.1–2.5 mm), 1.9 mm (IQR 1.3–2.7 mm), and 3.1 mm (IQR 
1.8–5.0 mm), respectively. The systematic errors (Σ) in the ML, CC, and AP axes were 1.17 mm, 2.83 mm, and 
1.75 mm, respectively. The random errors (σ) in the corresponding directions were 1.37 mm, 2.52 mm, and 
1.95 mm, respectively.
Intrafractional movement. For intrafractional movement, median values of median shifts in the ML, 
CC, and AP axes were 2.1 mm (IQR 1.5–3.2 mm), 1.9 mm (IQR 1.0–2.7 mm), and 2.3 mm (IQR 1.4–3.7 mm), 
respectively. Of the total 1,483 fractions, significant intrafractional displacement occurred 5 times (0.34%) in 
the ML direction, 11 times (0.74%) in the CC direction, and 18 times (1.21%) in the AP direction. A total of 7 
patients showed significant intrafractional displacement in one or more axes at least once during the treatment 
course. Of the 7 patients, 1 showed significant intrafractional displacement in all axes; 3 patients, in two of the 
three axes; and 3 patients, in one axis (one for each of the ML, CC, and AP axes). Median intrafractional move-
ment in the ML, CC, and AP axes for the 7 patients was 3.3 mm, 3.4 mm, and 5.8 mm, respectively. The number 
of significant intrafractional displacements in each patient ranged from 1 to 10. One patient receiving 16 frac-
Figure 1.  Distribution of median interfractional displacements in the three major axes. The top end and the 
bottom end of the error bar are the maximum and minimum value excluding outliers of the interfractional 
displacements of three axes, respectively. The outliers were defined as larger (smaller) values than the upper 
(lower) boundary, which were defined as 1.5 IQR above (below) 75th (25th) percentile. Figure created in IBM 
SPSS, version 23.0 (https ://www.ibm.com/analy tics/spss-stati stics -sofwa re).
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tions of HT-CSI experienced 10 significant displacements and showed nausea grade 2+ and weight loss of 3.7% 
compared to the baseline weight.
Multivariate analysis revealed that only weight loss grade 1+ was a risk factor for significant intrafractional 
displacement (odds ratio, 8.10, 95% CI: 1.47–44.58, p = 0.016, Table 2).
Subgroup analysis of pediatric and adult patients. Pediatric and adult patients were defined as 
patients below and above the age of 20 years, and the patient and treatment characteristics of each group are 
listed in Supplementary Table S1.
For 40 pediatric patients, median interfractional shifts in the ML, CC, and AP axes were 1.6 mm (IQR 
1.1–2.4 mm), 1.9 mm (IQR 1.3–2.7 mm), and 3.4 mm (IQR 1.8–5.1 mm), respectively. Of the total 7 patients 
with significant intrafractional displacement in one or more axes at least once during the treatment period, 5 
were pediatric patients. In both univariate and multivariate analyses, weight loss grade 1+ was found to be a risk 
factor for significant intrafractional displacement (odds ratio, 11.63, 95% CI: 1.47–92.14, p = 0.020, Table 3).
In the 43 adult patients, median interfractional shifts in the ML, CC, and AP axes were 1.7 mm (IQR 
1.1–2.6 mm), 1.9 mm (IQR 1.2–3.0 mm), and 2.9 mm (IQR 1.8–4.5 mm), respectively. Two adult patients 
showed significant intrafractional displacement in one or more axes at least once during the treatment period. 
Of the two patients, one patient was 20 years old, the youngest among adult patients. No factor was significantly 
associated with significant intrafractional displacement in both univariate and multivariate analyses (Table 4).
Discussion
In this study, to demonstrate the feasibility of CSI using HT, we evaluated the accuracy of setup in interfractional 
and intrafractional movements based on setup errors and patient movement during treatment, respectively. 
In addition, we identified the risk factors for intrafractional movement using clinically/statistically significant 
features.
In terms of interfractional setup errors, the median of the interfractional setup errors were less than or equal 
to 3.1 mm in the ML, CC, and AP axes. The maximum systematic and random errors along the ML, CC, and 
Table 2.  Risk factors for significant intrafractional movement. OR odds ratio; CI confidence interval; BMI 
body-mass index; CSI craniospinal irradiation. *BMI and total CSI dose was treated as a continuous variable. 
The foreparts of the parentheses were set as the reference groups in the multivariable analysis.
Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Age (< 20 years vs. ≥ 20 years) 0.34 (0.06–1.87) 0.216
BMI* 0.87 (0.71–1.07) 0.191
Total CSI dose* 1.00 (1.00–1.00) 0.957
Beam on time (< 8 min vs. ≥ 8 min) 1.63 (0.30–8.95) 0.574
Concurrent chemotherapy (No vs. Yes) 5.42 (0.98–29.94) 0.053 4.24 (0.71–25.43) 0.114
Overall CSI treatment time (< 32 days vs. ≥ 32 days) 0.36 (0.07–1.97) 0.239
Sedation during treatment (No vs. Yes) 0.00 (0.00–0.00) 0.999
Medically-indicated treatment interruptions (No vs. Yes) 0.76 (0.14–4.24) 0.763
Weight loss (Grade < 1 vs. Grade ≥ 1) 9.93 (1.91–51.72) 0.006 8.10 (1.47–44.58) 0.016
Nausea (Grade < 2 vs. Grade ≥ 2) 5.00 (1.01–24.65) 0.048
Table 3.  Risk factors for significant intrafractional movement in pediatric patients. OR odds ratio; CI 
confidence interval; BMI body-mass index; CSI craniospinal irradiation. *BMI and total CSI dose was treated 
as a continuous variable. The foreparts of the parentheses were set as the reference groups in the multivariable 
analysis.
Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
BMI* 0.83 (0.64–1.08) 0.162
Total CSI dose* 1.00 (1.00–1.00) 0.156
Beam on time (< 8 min vs. ≥ 8 min) 1.42 (0.21–9.55) 0.721
Concurrent chemotherapy (No vs. Yes) 6.21 ×  108 (0.00–0.00) 0.998
Overall CSI treatment time (< 24 days vs. ≥ 24 days) 0.71 (0.11–4.76) 0.721
Sedation during treatment (No vs. Yes) 0.00 (0.00–0.00) 0.999
Medically-indicated treatment interruptions (No vs. Yes) 0.42 (0.04–4.20) 0.463
Weight loss (Grade < 1 vs. Grade ≥ 1) 11.63 (1.47–92.14) 0.020 11.63 (1.47–92.14) 0.020
Nausea (Grade < 2 vs. Grade ≥ 2) 1.93 (0.28–13.44) 0.509
5
Vol.:(0123456789)
Scientific Reports |         (2021) 11:6120  | https://doi.org/10.1038/s41598-021-85574-y
www.nature.com/scientificreports/
AP directions were 2.83 mm and 2.52 mm, respectively, which were found to correspond to the results of previ-
ous studies by Al-Wassia et al. and Thondykandy et al. (range, 1.1–2.7 mm and 1.9–2.2 mm, respectively)32,33.
In terms of intrafractional movement, the overall patient group showed less than or equal to 2.3 mm of 
median intrafractional movement in every direction. Median intrafractional movements in both pediatric and 
adult patients were not significantly different. Multivariate logistic regression analyses in all patients showed 
that weight loss grade 1+ was a risk factor for significant intrafractional movement. The results of the subgroup 
analysis showed that weight loss grade 1+ was a risk factor for significant intrafractional movement in the pedi-
atric patient group, but no risk factor was reported in the adult patient group.
Several studies have reported that weight loss affects interfractional set up  errors34,35, but there is no report 
on intrafractional movement. The association between weight loss and intrafractional movement in our study 
can be discussed in terms of the following two aspects: first, due to toxicity or nausea induced by a high radiation 
dose during RT, the patient’s appetite deteriorates, leading to a poor condition; therefore, the weight decreases 
with progression of the treatment. Second, the patient will not be able to maintain a constant posture during 
treatment because of irresistible movement caused by nausea or dizziness due to RT or chemotherapy; thus, 
significant intrafractional movement might be induced.
There are three major limitations to this study. First, although HT can technically scan up to 300 slices, a 
long-range MVCT scan has not been used in this study, which can be thought of as a limitation of this study. 
However, in the case of long-range MVCT scan, as the scanning time increases due to its range of long-range 
MVCT scan, the imaging dose delivered to the patient and the possibility of additional movement of the patient 
can be increased. Therefore, the long-range MVCT scan was not used when registering the HT-CSI in this study. 
Second, in HT-CSI protocol of Yonsei Cancer Center, the range of pre-treatment MVCT is from the zygomatic 
arch to the C4 spine. With the registration of this pre-treatment MVCT and planning CT, it is confirmed that the 
patient’s position before the treatment is same as that of the planning CT under the assumption that the posi-
tion of the whole body can be confirmed with the pre-treatment MVCT. Through this assumption, is possible to 
reduce the image dose and treatment time, but it is not certain that the range of pre-treatment MVCT and the 
whole body are perfectly synchronized in the same state with the planning CT. To minimize this uncertainty, a 
line is drawn along the midline of the patient’s body during the simulation. This line is aligned with the room 
laser before each treatment, and pre-treatment MVCT is taken in this state. With this line and laser, the spinal 
position of the patient in planning CT is synchronized with the cranial position in pre-treatment (verified with 
pre-treatment MVCT), and can be synchronized with the spinal position in pre-treatment, which can be the basis 
of the assumptions: position of the whole body can be confirmed with the pre-treatment MVCT. Additionally, 
considering this assumption and following uncertainty, the larger margin of the spine was applied than that of 
the brain. However, despite these protocols, there is still a question of perfect synchronization between spinal 
position in pre-treatment and planning CT cannot be guaranteed. Therefore, further study regarding the effect 
of this synchronization and uncertainty would be needed to compensate this limitation. Third, in the interfrac-
tional setup error analysis, the overestimation of interfractional setup error may be induced. For example, in 
case of patients who had an incorrect initial positioning during simulation but did not re-simulate, it can be 
evaluated that these patients represent a large interfractional error despite they did not show the significantly 
different location in each fraction. The fact that these patients have large interfractional error but did not have 
clinically significant conditions due to little difference between each fraction can indicate that using the median 
difference between the patient location in each fraction and planning as an interfractional setup error can over-
estimate the uncertainty in the setup. These patients who repetitively showed large setup errors were included 
in the pediatric group; the patient needs to relax and adjust to a comfortable and repeatable position during 
simulation, and this would be difficult considering that pediatric patients could be particularly nervous during 
the whole RT procedure.
Additionally, when it comes to planning CT images, 3 mm or smaller CT slice thickness would be more 
appropriate compared with our setup errors (around 3 mm). However, in case of planning CT for CSI, there could 
Table 4.  Risk factors for significant intrafractional movement in adult patients. OR odds ratio; CI confidence 
interval; BMI body-mass index; CSI craniospinal irradiation. *BMI and total CSI dose was treated as a 
continuous variable. The foreparts of the parentheses were set as the reference groups in the multivariable 
analysis.
Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
BMI* 1.54 (0.74–3.23) 0.251
Total CSI dose* 0.99 (0.99–1.00) 0.228 1.00 (1.00–1.00) 0.115
Beam on time (< 8 min vs. ≥ 8 min) 1.15 ×  108 (0.00–0.00) 0.999
Concurrent chemotherapy (No vs. Yes) 0.00 (0.00–0.00) 0.999
Overall CSI treatment time (< 35 days vs. ≥ 35 days) 0.95 (0.06–16.28) 0.973
Sedation during treatment (No vs. Yes) 0.00 (0.00–0.00) 0.999
Medically-indicated treatment interruptions (No vs. Yes) 2.15 (0.13–37.19) 0.598
Weight loss (Grade < 1 vs. Grade ≥ 1) 7.20 (0.39–134.22) 0.186 38.13 (0.41–3538.38) 0.115
Nausea (Grade < 2 vs. Grade ≥ 2) 4.62 ×  102 (0.00–0.00) 0.998
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:6120  | https://doi.org/10.1038/s41598-021-85574-y
www.nature.com/scientificreports/
be possible hazard of additional imaging dose to the patient and the movement of patient due to the required 
additional time with smaller slice thickness compared to current 3 or 5 mm.
Despite these limitations, our research has three strengths. First, our study analyzed 1,483 fractions in a total 
of 83 patients who received CSI, which is the largest number of patients analyzed with respect to CSI studies 
using HT. Second, while most of the HT-CSI studies analyzed either interfractional setup errors or intrafractional 
movement, our study is the only one to analyze and report both error and movement. Finally, to date, no attempt 
has been made to incorporate clinical factors into HT-CSI-related set up errors, and this is the first study to 
closely analyze clinical factors related to intrafractional movement.
In conclusion, our findings have demonstrated that HT-CSI would be clinically feasible in terms of interfrac-
tional setup errors and intrafractional movements. The effect of difference in scan range of pre- and post- MVCT 
to setup uncertainty should be analyzed to increase the accuracy of the interfractional setup error. To minimize 
intrafractional movements in HT-CSI, treatment can be carried out by paying attention to weight loss using best 
supportive care during CSI. Particularly, for pediatric patients with severe weight loss, delicate monitoring during 
treatment setup and conservative management are required to maintain the required weight.
Materials and methods
Patient selection. CSI using helical TomoTherapy (Accuray Inc., Sunnyvale, CA, USA) has been utilized 
in Yonsei Cancer Center from 2014. Patients who received HT-CSI between January 2014 and December 2018 
were screened (n = 99). Patients were excluded from the study if they met one of the following criteria: (1) they 
received HT-CSI combined with 3D-CRT (n = 3), (2) they could not complete RT (n = 10), and (3) they did 
not have any record for translational displacements obtained through MVCT (n = 3). Finally, 83 patients were 
included in our cohort. Among 83 patients, 21, 42, 19 and 1 patients received HT-CSI using Hi-Art, Tomo-HD, 
Tomo-HDA and Radixact, respectively.
This study was approved by the Severance Hospital institutional review board (No. 4–2020-0046), and the 
requirement for informed consent was waived because of the retrospective nature of this study. All methods were 
carried out in accordance with relevant guidelines and regulations.
Simulation, treatment planning, and treatment setup. For posture fixation in patients during HT-
CSI, the head and neck were immobilized with a thermoplastic mask in the supine position, and the entire body 
was immobilized with a Vac-Lok cushion (BlueBAG, Elekta, Stockholm, Sweden). A long line is drawn along 
the midline of the patient’s body to align the spine of the patient. Planning CT images were acquired with 3- or 
5-mm slice thickness and with intravenous contrast. The clinical target volume was defined as a 3-mm margin 
from the whole brain and spinal canal, inferiorly to the end of the dural sac. The planning target volume (PTV) 
was defined as the expansion of the clinical target volume with a 3-mm margin for the brain, 5-mm margin for 
the C1–T7 spine level, 7-mm margin for the T8–T12 spine level, and 10-mm margin for the L1 spine–sacral level 
in all directions (Fig. 2).
For each daily treatment, the patient’s posture was fixed with the devices described above as the first step, and 
then the treatment room laser was aligned to the marks of the Vac-Lok and the thermoplastic mask and to the 
midline of the patient’s body. Afterwards, an MVCT scan in the coarse mode was obtained from the zygomatic 
arch to the C4 spine level (Fig. 2A). The HT console software program can automatically register planning CT 
images using MVCT and determine the direction of PTV displacement with regard to the isocenter. After auto-
matic registration, radiation therapists slightly adjusted the registration manually if necessary. After adjustment, 
the couch was moved in the ML, CC, and AP directions to the correct setting. In terms of the possible rotational 
error, every setup was under rotational correction by re-setup when the rotation of pitch/yaw direction more 
than 1 degree or roll direction more than 2 degrees occurs. Then, pitch and yaw error which were lower than 1 
degree were neglected, and the roll correction was registered automatically by HT.
Figure 2.  Target delineation for craniospinal irradiation (green line, clinical target volume [CTV]; blue line, 
planning target volume [PTV]) (A) Range of daily pre-treatment megavoltage computed tomography (MVCT). 
(B) Range of daily post-treatment MVCT.
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After each fractional treatment was delivered, a post-treatment MVCT scan in the coarse mode was acquired 
(from the T12 spine to L4 spine) (Fig. 2B). Additionally, post-treatment MVCT images were compared with 
planning CT images, and the movement in each axis during treatment was determined.
Analysis of interfractional and intrafractional errors. For the analyses of interfractional and intra-
fractional errors, both pre- and post-treatment MVCT images of a total of 1,483 fractions in 83 patients were 
analyzed.
Interfractional setup errors are measurements used for quantifying the day-to-day difference, which are 
obtained from the translational displacement values in each axis after scanning pre-treatment MVCT. The median 
displacement in each axis was obtained during the course of the treatment for each patient. To describe the dis-
persion of the interfractional setup error, the interquartile range, which means the middle 50% of values sorted 
from lowest to highest, was used. Moreover, systematic error (Σ) and random error (σ) were calculated, wherein 
systematic error represents uncertainties in the treatment procedure or the system itself, and random error liter-
ally represents the random error that includes daily fluctuations in patient motion or internal organ  motion32. 
Systematic error was calculated as the standard deviation of the average setup error of each patient throughout the 
whole fractions. Random error was calculated as the root mean square of the standard deviations in each patient 
over the whole patient  group33. Intrafractional movements were evaluated on the post-treatment MVCT scan at 
each fraction. Moreover, the median values of displacement from post-treatment MVCT scans were calculated 
for whole fractions in each patient. Concerning the PTV margin at the L-S spine level, significant intrafractional 
displacement was defined as a displacement of > 10 mm in any axis in any fraction.
Risk factors for intrafractional movement. Logistic regression analysis was used to identify risk factors 
for intrafractional movement. Statistically significant factors and clinically relevant factors (age, BMI, weight 
loss, rest during treatment, nausea, sedation during treatment, concurrent chemotherapy, total HT-CSI dose, 
total duration of HT-CSI, and beam on time) were determined via univariate and multivariate analyses. Patients’ 
body weight values determined on the first and last treatment days were used to calculate the rate of body weight 
change. Multivariate logistic regression analysis was then conducted using the backward stepwise selection pro-
cedure. All p values lower than 0.05 were considered statistically significant. Statistical analysis was performed 
using IBM SPSS, version 23.0 (IBM Corp., Armonk, NY, USA).
Data availability
There are no restrictions on the availability of materials or information. The datasets generated during and/or 
analyzed during the current study are available from the corresponding author on reasonable request.
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